A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

Janssen Research & Development, LLC21 enrolled

Overview

The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.

This is a multicenter (when more than one hospital or medical school team work on a medical research study) study which includes an initial unmasked safety phase. The duration of participation in the study for each participant is approximately 3 years. Efficacy will be evaluated at 6 months, 12 months and annually thereafter. Participants' safety will be monitored throughout the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Visual Acuity Geographic Atrophy Macular Degeneration

Interventions

CNTO 2476 3.0 x 10^5 cellsDRUG

Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.

Subretinal Delivery SystemDEVICE

Participants will receive CNTO 2476 by using the Delivery System.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) confirmed within 45 days prior to initial randomization verified by the central reading center * Study eyes will have a best corrected visual acuity (BCVA) of 20/80 to 20/800 \[Early Treatment Diabetic Retinopathy Study (ETDRS) log of the minimum angle of resolution (logMAR) value 0.6-1.6\]. The treatment eye will be that with the worse BCVA at Screening. If BCVA is clinically equivalent, the eye with the larger GA determines the study eye * Participant is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures. Participant has met criteria of the surgery center anti-coagulation protocol, if applicable * Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: * Participant has a history of neovascular ("wet") AMD in the treatment eye, including evidence of retinal pigment epithelium rips or evidence of subretinal or choroidal neovascularization or fluid. In cases where imaging is inconclusive, review of the case with the study site, considering history and imaging will determine eligibility. History or evidence of neovascular AMD in the fellow eye is allowed, if anti-vascular endothelial growth factor (VEGF) therapy has not been required for at least 8 weeks prior to Screening * Geographic atrophy secondary to any causes other than AMD in either eye * A diagnosis of glaucoma with an intraocular pressure (IOP) greater than or equal to (\>=) 25 millimeter of mercury (mmHg) while being treated with an ocular hypotensive drug. Treatment should be no more than 1 drug preparation/combination, which can contain 1 or 2 ocular hypotensive active ingredients; participants receiving more than 2 ocular hypotensive active ingredients are excluded * Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above Grade 2 per Age Related Eye Disease Study (AREDS) scale or any other ophthalmologic condition that reduces the clarity of the media that, in the opinion of the investigator or reading center, interferes with ophthalmologic examination (example, corneal abnormalities, inadequate pupillary dilation), surgery or imaging in the study eye * Myopia greater than minus (\>-) 8 diopters and participants with greater than (\>) 4 diopters of astigmatism, and greater than plus (\>+) 10 diopters of hyperopia

Locations (8)

Unnamed facility

Arcadia, California, United States

Unnamed facility

Chicago, Illinois, United States

Unnamed facility

Lexington, Kentucky, United States

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 1- Treated Eye

Best corrected visual acuity (BCVA) was assessed in the study eye (Treated eye). BCVA measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there were 5 letters per line, the total score for a line on the logMAR chart represented a change of 0.1 log units. The formula for calculating the logMAR BCVA score was: 1.7 - 0.02\*number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

Time frame: Baseline and Month 1

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 2- Treated Eye

BCVA was assessed in the study eye (Treated eye). BCVA measurements were made using the logMAR visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there were 5 letters per line, the total score for a line on the logMAR chart represented a change of 0.1 log units. The formula for calculating the logMAR BCVA score was: 1.7 - 0.02\*number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

Time frame: Baseline and Month 2

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 3- Treated Eye

Time frame: Baseline and Month 3

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 6- Treated Eye

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Royal Oak, Michigan, United States

Unnamed facility

Cincinnati, Ohio, United States

Unnamed facility

Philadelphia, Pennsylvania, United States

Unnamed facility

Dallas, Texas, United States

Time frame: Baseline and Month 6

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 12- Treated Eye

Time frame: Baseline and Month 12

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 18- Treated Eye

Time frame: Baseline and Month 18

Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 24- Treated Eye

Time frame: Baseline and Month 24

Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 30- Treated Eye

Time frame: Baseline and Month 30

Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 36- Treated Eye

Time frame: Baseline and Month 36

Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 1- Fellow Eye

BCVA was assessed in the fellow eye. BCVA measurements were made using the logMAR visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there were 5 letters per line, the total score for a line on the logMAR chart represented a change of 0.1 log units. The formula for calculating the logMAR BCVA score was: 1.7 - 0.02\*number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

Time frame: Baseline and Month 1

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 2- Fellow Eye

Time frame: Baseline and Month 2

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 3- Fellow Eye

Time frame: Baseline and Month 3

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 6- Fellow Eye

Time frame: Baseline and Month 6

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 12- Fellow Eye

BCVA was assessed in the fellow eye. BCVA measurements were made using logMAR visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there are 5 letters per line, the total score for a line on the logMAR chart represents a change of 0.1 log units. The formula for calculating the logMAR BCVA score is: 1.7 - 0.02\*number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

Time frame: Baseline and Month 12

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 18- Fellow Eye

Time frame: Baseline and Month 18

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 24- Fellow Eye

Time frame: Baseline and Month 24

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 30- Fellow Eye

Time frame: Baseline and Month 30

Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 36- Fellow Eye

Time frame: Baseline and Month 36

Secondary Outcomes

Percentage of Participants Losing Greater Than or Equal to (>=) 15 Best Corrected Visual Acuity Letters: Treated Eye

BCVA was assessed as letters read using early treatment diabetic retinopathy study charts and reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye (Treated eye). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The percentage of participants losing \>=15 BCVA in the study eye were reported.

Time frame: Months 1, 2 , 3, 6, 12, 18, 24, 30 and 36

Percentage of Participants Losing >=15 Best Corrected Visual Acuity Letters: Fellow Eye

BCVA was assessed as letters read using early treatment diabetic retinopathy study charts and reported as the number of letters read correctly (ranging from 0 to 100 letters) in the fellow eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The percentage of participants losing \>=15 BCVA in the fellow eye were reported.

Time frame: Months 1, 2 , 3, 6, 12, 18, 24, 30 and 36

Change From Baseline in Best Corrected Visual Acuity Letters at Months 6 and 12: Treated Eye

Time frame: Baseline, Months 6 and 12

Change From Baseline in Best Corrected Visual Acuity at Months 6 and 12: Fellow Eye

BCVA was assessed as letters read using early treatment diabetic retinopathy study charts and reported as the number of letters read correctly (ranging from 0 to 100 letters) in the fellow eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame: Baseline, Months 6 and 12

Change From Baseline in Growth Rate of Geographic Atrophy (GA) Lesion Area at Months 6 and 12: Treated Eye

The area of GA was determined based primarily on fundus autofluorescence (FAF). The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

Time frame: Baseline, Months 6 and 12

Change From Baseline in Growth Rate of Geographic Atrophy Lesion Area at Months 6 and 12: Fellow Eye

The area of GA was determined based primarily on FAF. The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

Time frame: Baseline, Months 6 and 12

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Number of participants with TEAEs and SAEs were assessed. An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment and can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product.

Time frame: Up to Months 36

Number of Participants With Ocular Treatment-emergent Adverse Events

Number of participants with ocular TEAE were assessed. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment and can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.

Time frame: Up to Months 36